Suchergebnisse - "Buti, Maria"

PubPharm (49)

1

In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments

enthalten in: International journal of molecular sciences | 2023

von Colomer-Castell, S. | Gregori, J. | Garcia-Cehic, D. | +12

2

Quasispecies Fitness Partition to Characterize the Molecular Status of a Viral Population. Negative Effect of Early Ribavirin Discontinuation in a Chronically Infected HEV Patient

enthalten in: International journal of molecular sciences | 2022

von Gregori, J. | Colomer-Castell, S. | Campos, C. | +17

3

Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Younossi, Z. | Racila, A. | Muir, A. | +14

4

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6

enthalten in: Journal of viral hepatitis | 2019

von Lawitz, E. | Gane, E. | Feld, J. | +56

5

Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin

enthalten in: Transfusion | 2018

von Riveiro-Barciela, M. | Bes, M. | Quer, J. | +9

6

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

enthalten in: Gastroenterology | 2018

von Esteban, R. | Pineda, J. | Calleja, J. | +19

CommentIn: Gastroenterology. 2018 Oct;155(4):969-971. - PMID 30201359

7

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B) : two randomised, phase 2, open-label trials

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Lawitz, E. | Buti, M. | Vierling, J. | +26

CommentIn: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):771-772. - PMID 28802817

8

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease : Analysis of data from the Hepa-C registry

enthalten in: Hepatology (Baltimore, Md.) | 2017

von Fernández Carrillo, C. | Lens, S. | Llop, E. | +27

CommentIn: Hepatology. 2017 Jun;65(6):1789-1791. - PMID 28318048

9

The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis : A Cost-Effectiveness Analysis

enthalten in: Transplantation | 2017

von Tapper, E. | Hughes, M. | Buti, M. | +5

10

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

enthalten in: PloS one | 2017

von Asselah, T. | Moreno, C. | Sarrazin, C. | +12

1
2
3
4
5
Nächster »
[5]